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Does routine surveillance imaging after
completing treatment for childhood solid
tumours cause more harm than good? A
systematic review and meta-analysis
protocol
Jessica E. Morgan* , Melissa Harden and Robert S. Phillips
Abstract
Background: This systemic review aims to synthesise the current literature surrounding off-therapy surveillance
imaging in children and young people with extra-cranial solid tumours, with a view to establishing if routine
imaging studies after treatment for childhood cancer increase overall survival, increase the psychological distress
caused to patients and families, result in other harms to patients and are cost-effective strategies. Within this
manuscript, we also describe how patient and public involvement has impacted upon the protocol.
Methods: The search will cover thirteen different databases, key conference proceedings and trial registers, as well
as reference lists and forward citations of included papers. Prominent authors/clinicians in the field will be
contacted. A full search strategy is provided. The study designs to be included in the review will be added in
an iterative way (RCTs, quasi-randomised trials, prospective cohorts and retrospective cohorts). Qualitative
studies will also be eligible for inclusion. We will include studies which examine a programme of surveillance
imaging that aims to detect relapse in children or young people up to age 25 years who have completed
treatment for a malignant extracranial solid tumour and have no evidence of active and ongoing disease at
end of treatment. The primary outcome is overall survival, with secondary outcomes including psychological
distress indicators, number of imaging tests performed, other harms of imaging and cost-effectiveness
measures. Studies will be screened and data extracted by two researchers. Studies will be critically appraised
using a stratified version of the ROBINS-I tool. Where appropriate, data will be synthesised using a random
effects meta-analysis. A detailed analysis plan, including assessment of heterogeneity and publication bias, is
provided.
Discussion: The aim of routine surveillance imaging is to detect recurrence of disease before clinical symptoms and signs
develop. Some studies have suggested that most relapses of childhood cancer are detected due to clinical symptoms or
signs, particularly in those with extra-cranial solid tumours, and when these relapses are detected by imaging, there is no
increase in survival. This review aims to establish whether routine surveillance imaging is beneficial, as well as evaluating the
potential negative impacts of surveillance programmes.
Systematic review registration: PROSPERO CRD42018103764
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Background
The follow-up of children and young people who have
been treated for extra-cranial solid tumours currently in-
volves a series of clinical reviews, along with imaging
studies such as chest X-rays, CT or MRI scans or
nuclear imaging, the exact nature of which is tailored to
the original disease and directed by local protocols and
traditions. The aim of providing regular imaging in this
off-treatment phase is to detect recurrence of disease
before clinical symptoms and signs develop and to estab-
lish any long-term complications of therapy [1].
The rationale for routine imaging for this group relies
on a number of unproven assumptions [2]. The first of
these is that this imaging will detect recurrence of can-
cer before the child develops clinical symptoms of the
disease. The second is that because of this earlier detec-
tion, there will be treatment options available that would
not be available later or would be more effective if given
earlier. Finally, and most importantly, is the assumption
that detecting a relapse at an earlier stage will prevent
the child from dying of their cancer. Unfortunately, this
may not be the case. Some studies have suggested that
most relapses of childhood cancer are detected due to
clinical symptoms or signs, particularly in those with
extra-cranial solid tumours, and when these relapses are
detected by imaging, there is no increase in survival [1,
3, 4]. However, as relapsed disease in children is thank-
fully rare, there are very small studies which have not
been powered to detect even relatively large differences
in survival of over 10% [3].
The answer to this systematic review’s main question
is important to establish as routine imaging programmes
carry a number of disadvantages. There is growing evi-
dence that even relatively small amounts of radiation,
such as that involved in a single CT scan, can signifi-
cantly increase the risk of malignancy [2]. In children
who may already be predisposed to developing cancer,
performing additional CT scans may provide long-term
risks. For very young children who require repeated gen-
eral anaesthetics for their imaging, there are additional
risks to their health. Furthermore, many families de-
scribe that routine follow-up imaging causes anxiety and
distress, particularly whilst awaiting results. This may be
avoided if routine imaging was found to be unnecessary.
An additional disadvantage to regular imaging is the risk
of false-positive findings, which result in unnecessary
tests, treatment and further distress for the patient and
family [4].
Finally, routine imaging programmes involve a number
of costs. Families may incur transport and parking costs,
as well as loss of work productivity, due to additional
visits to the hospital. For the hospital itself, there are the
costs of performing and interpreting the scans, as well
as the staff and resource time in using imaging
departments for this purpose. The opportunity costs
may be marked when considered in terms of the number
of images involved.
We therefore propose that a systematic review aiming
to gather together all studies that have ever addressed
the question of routine imaging may reach the numbers
of patients necessary to provide a more precise answer
to whether surveillance imaging is beneficial in terms of
survival, in all children or in specific tumour groups. As
far as we are aware, no such systematic review has previ-
ously been performed for this population group. For the
purpose of this review, the term “child” or “childhood”
refers to any child, adolescent or young adult up to the
age of 25 years.
Patient and public involvement group
The patient and public involvement (PPI) group for this
research was a mixed group of young people who had
been treated for a childhood cancer and parents of chil-
dren who had been treated. Some parents had experi-
ence of a relapse of their child’s cancer, and some of
their children had died. Some of the people who had
had cancer had been treated as young children, and
some had been treated as teenagers. The cancers experi-
enced by the PPI group included neuroblastoma, clear
cell sarcoma of the kidney, germ cell tumour, Ewing’s
sarcoma and retinoblastoma. The group was invited
through parent organisations (including the Children’s
Cancer and Leukaemia Group (CCLG), Candlelighters
Children’s Cancer Charity and Paediatric Oncology Ref-
erence Team (PORT)) as well as through Twitter and
Facebook groups. Different members of the group had
different social backgrounds and experiences. Three
members of the group met with JM and RSP at a project
inception event, in June 2018. Other members of the
group provided input via telephone conversations with
JM before or after the group.
Ultimately, the PPI group input has significantly chan-
ged the focus and design of this research, particularly
changing the balance of the work to include more of the
psychological and experiential aspects of surveillance
imaging. Firstly, we recognised a need to change the title
of the work to capture more accurately the concerns of
these key stakeholders—whilst survival is important, it is
not the only outcome to be considered. Therefore, the
review title now captures the aims of establishing both
benefits and harms of routine surveillance imaging.
Secondly, the PPI group has helped to create an order
of priority for the work, including what research should
be recommended if gaps appear in the current literature.
All group members felt that the survival question was
the first factor to explore and this informs all the follow-
ing issues. We are also aware that the survival question
is the area that is most likely to have sufficient data
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within the existing literature. Following on from the sur-
vival question, the anxiety and certainty issues were felt
to be the next most important questions to answer
within this review. We are aware the psychological
health impacts may be less robustly researched.
Thirdly, the group has helped to focus the team’s
attention psychological outcomes, as well as the role of
timing and social setting on the experience of surveil-
lance imaging. Two outcomes that we had not initially
planned to include in the review, but which now form
part of the protocol, are the rate of detection of “indeter-
minate” findings and the number of imaging tests per-
formed that do not form part of the routine surveillance
(so as to try to answer the issue of whether surveillance
imaging reduces imaging exposure). We will now be
seeking a broader range of research for inclusion within
the review, including qualitative and survey data that
attempts to capture experiences of surveillance imaging
following childhood cancer alongside the quantitative
data surrounding survival and costs.
Finally, the PPI group has helped to shape and clarify
a dissemination plan for the research—emphasising the
importance of certain stakeholders. The whole group
has shared their keenness to continue to be involved in
the work of this project, and we appreciate their input.
Aims, objectives and overview of systematic
review
To systemically review, critically appraise and synthesise
the current literature surrounding off-therapy surveil-
lance imaging in children and young people with extra-
cranial solid tumours, in high-income countries, with a
view to establishing if routine imaging studies after treat-
ment for childhood cancer:
 Increase overall survival
 Increase the psychological distress caused to patients
and families
 Result in other harms to children and young people
 Are cost-effective strategies
Methods
This protocol is presented according to the PRISMA-P
guidelines for the presentation of systematic review pro-
tocols (see Additional file 1) [5]. The work has been reg-
istered at PROSPERO ref: CRD42018103764.
Search and retrieval strategy
The following databases will be searched to identify rele-
vant studies: MEDLINE (Epub Ahead of Print, In-
Process & Other Non-Indexed Citations, Ovid MED-
LINE Daily and Ovid MEDLINE), PubMed, EMBASE,
PsycINFO, Cumulative Index to Nursing & Allied Health
(CINAHL Plus), Science Citation Index, Conference
Proceedings Citation Index – Science, Cochrane Data-
base of Systematic Reviews (CDSR), Cochrane Central
Register of Controlled Trials (CENTRAL), Health
Technology Assessment database, Database of Abstracts
of Reviews of Effects, NHS Economic Evaluation Data-
base (NHS EED) and EconLit. The search strategy for
MEDLINE has been developed by an information spe-
cialist (MH) with input from the review team. The strat-
egy comprises of subject headings and free-text terms
for children/young people, cancer, imaging tests and sur-
veillance (see Additional file 2). The MEDLINE strategy
will be adapted as necessary for the other sources
searched.
Conference proceedings of the RCPCH (Royal College
of Paediatrics and Child Health), SIOP (International Soci-
ety of Paediatric Oncology), ASPHO (American Society of
Pediatric Hematology/Oncology), ASCO (American Soci-
ety of Clinical Oncology) and ASH (American Society of
Hematology) meetings will be searched for relevant
abstracts. ClinicalTrials.gov and the WHO International
Clinical Trials Registry Platform portal will be searched
for relevant ongoing work. Reference lists of relevant sys-
tematic reviews and included articles will also be reviewed.
Forward citation searching of included articles will be per-
formed, using Web of Science. Authors of relevant studies
may be contacted as time allows to seek further studies.
Published and unpublished studies will be sought and no
language, geographical or study design restrictions
applied. Non-English language studies will be translated if
time permits. Searches will be limited to studies from
1990 onwards, to reflect the current era of survival in
childhood cancer.
Screening for eligibility
Screening and data extraction will be managed using
EPPI-Reviewer 4 [6]. Two reviewers (JM and another
researcher) will independently screen the title and ab-
stract of studies for inclusion. After each 10% portion
of the records has been screened, the rate of agreement
between reviewers will be assessed. Once an adequate
rate of agreement has been reached (> 90% agreement),
the remaining records will be split between the two re-
viewers and single screened. Full texts of studies which
might be relevant will then be sought and assessed fur-
ther, using the study eligibility decision form (Appendix
1). Full-text screening will be performed by two inde-
pendent researchers. Disagreements will be resolved by
consensus or, if this proves impossible, by recourse to
an independent adjudicator (RSP).
Inclusion and exclusion criteria for quantitative studies
Study design
The study designs to be included in the review will be
added in an iterative way. Initially, we will use
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randomised controlled trials (RCTs) and quasi-
randomised trials to attempt to answer the research
aims. If, as we suspect, there are insufficient studies of
these designs, we will then move to include prospective
cohort studies and re-evaluate the data. Finally, should
the research objectives not be met using these study de-
signs, we will then go on to consider the inclusion of
retrospective studies. Surveys of patient or provider
opinions will not be actively sought in this review, but
when identified will be included within the narrative re-
view as they may provide insight into experiences and
priorities that are not found elsewhere. Case studies will
not be eligible for inclusion within the review. We ac-
knowledge the progressive increase in risk of bias as we
move through this strategy, and these challenges will be
discussed within our reports and publications.
Population
The study will include children or young people up to
age 25 years who have completed treatment for a malig-
nant extracranial solid tumour and have no evidence of
active and ongoing disease at the end of treatment. This
may include patients with residual abnormalities which
are deemed to be stable at the time of entry to the study.
Tumour types include but are not limited to neuroblast-
oma, Wilms’ tumour, soft tissue sarcoma (including
rhabdomyosarcoma), Hodgkin’s lymphoma, malignant
bone tumours (including osteosarcoma and Ewing’s sar-
coma) and extra-cranial germ cell tumours.
Studies where the majority (> 50%) of patients are aged
less than 25 years will be included, even if children and
young people are not reported separately, particularly if
the tumour type is reported (for example, neuroblast-
oma). If studies report a mixed population but data re-
lated to children and young people can be extracted
separately to older adults will be included.
Studies which evaluate screening programmes solely
related to the development of malignancies in patients
with cancer predisposition syndromes will not be eligible
for inclusion as these strategies have different aims and
objectives (namely detecting new-onset primary malig-
nancies rather than relapse).
We will not include studies from low- and middle-
income countries (LMICs) given the differences in dis-
ease presentation, management and risk of relapse
within these settings, which may result in different risks
and benefits from routine surveillance imaging. Given
that the results of this review are to be applied within
the HIC setting, we have specifically focused on studies
performed here.
Interventions and comparators
We are aware that studies are likely to include a wide
range of surveillance imaging strategies. For the purpose
of this review, studies must evaluate a programme of
surveillance imaging that aims to detect a relapse of pre-
viously treated childhood cancer, at the site of previous
disease or likely metastatic recurrence. Studies of sur-
veillance imaging programmes looking predominantly
for late effects of treatment will not be eligible for inclu-
sion as these form a different set of aims and objectives
and lie outwith the remit of this review. Non-
randomised and single-arm studies must examine the
surveillance imaging programme as the primary aim of
the study report. We anticipate that many of these stud-
ies will be performed as secondary studies running
alongside larger trials of upfront or relapse treatment
options.
The surveillance imaging programme must include
some form of radiological imaging, including (but not
limited to) X-ray, ultrasound and cross-sectional or nu-
clear imaging techniques.
Comparator groups within RCTs or cohort studies will
include routine follow-up without radiological imaging,
which result in “symptom or sign” based detection of re-
lapsed disease. Surveillance programmes which involve
routine clinical review and examination, including exam-
inations under anaesthesia (EUAs) for retinoblastoma,
will therefore form a comparator group rather than an
intervention. Studies comparing two different surveil-
lance imaging programmes will be eligible for inclusion.
Studies without a comparison group are eligible for in-
clusion, provided that they meet all other inclusion
criteria.
Outcomes
The selection of outcomes has been substantially in-
formed by the work with the PPI group for this research.
The group was very clear that overall survival was the
primary outcome for the review, with other secondary
outcomes being identified as listed.
Primary outcome:
 Overall survival (OS)—evaluated as age at the time
of death, or from date of original diagnosis. This
may be defined differently by each study, and
therefore, alternative definitions may be considered.
Importantly, studies reporting only survival from
diagnosis of relapse will not be included as this is
likely to be dependent upon the methods used for
detection of relapse and subsequently at risk of lead-
time bias.
Secondary outcomes:
 Psychological distress indicators—anxiety scores and
quality of life (QoL) scores, assessed over different
groups, including children, teenagers, parents and
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other family members (such as siblings and
grandparents)
 Other harms of imaging—including but not limited
to general anaesthetics required, second
malignancies, side effects of sedation and
“indeterminate” findings
 Number of imaging tests performed as part of
surveillance programme and number of imaging
tests performed not as part of surveillance
programme
 Cost-effectiveness measures, including diagnostic
yield per investigation
Inclusion and exclusion criteria for qualitative studies
Studies will be eligible for inclusion if they meet all of
the following criteria:
Study design
All studies using qualitative methodology will be eligible
for inclusion, including but not limited to ethnography,
phenomenology and grounded theory. Studies that use
qualitative methods but which do not state an explicit
methodology are also eligible to be included, provided
that they present qualitative data. This includes, but is
not limited to, studies using focus group discussions,
interview studies and observational studies. Similarly,
mixed methods studies are eligible for inclusion if they
provided sufficient data.
Study participants
The study participants will include patients, their parents/
carers, healthcare professionals, commissioners and/or
policy makers—though we anticipate that any available
data is most likely to have consulted parents, and occa-
sionally patients. We do not anticipate finding any qualita-
tive work of healthcare professionals, commissioners and/
or policy makers, but if this is present, it will be eligible
for inclusion. The topic of interest explored should be sur-
veillance imaging following treatment for paediatric extra-
cranial solid tumours.
Outcome of interest
Experiences of surveillance imaging.
Language
Qualitative data studies will be limited to those per-
formed and written in the English language. The benefit
of qualitative research is to allow participants to express
their experiences, the clarity of which could be lost
through translation and thus the results of the synthesis
may less accurately capture the views of participants.
Data extraction
Data will be extracted by one researcher using a standar-
dised data extraction form and independently checked
by a second (see Appendix 2 for the planned data vari-
ables). In addition, for studies describing categorical test
information, information will be extracted on any cut
points used (with the technique used for derivation of
cut points) and methods of statistical analysis, including
variables adjusted for. If the data to be extracted is
unclear, the corresponding author will be contacted for
further information. If there is no response, a further
attempt to make contact will be made a fortnight later.
If there is no response after a further 4 weeks, the data
will be presumed unavailable.
Assessment of risk of bias
The quality of studies will be assessed at outcome level
using a stratified version of the ROBINS-I tool, supple-
mented with information about potential sources of
heterogeneity: patient demographic and clinical charac-
teristics, study era, geography and antibiotic use [7, 8]. A
stratified version of the ROBINS-I tool is justified given
the significant increase in resources required for full use
of the tool. Instead, we will perform a simplified version
of the tool for all studies (see Appendix 3) and only
proceed to a full ROBINS-I assessment with studies
which are considered to be at low to moderate risk of
bias.
Methods of analysis/synthesis
Key study characteristics, the outcome data and study
quality will be summarised in narrative and tabular
forms. A mapping phase will be performed for the re-
view, clearly laying out the studies (and included data)
according to the relevant cancer type, imaging modality,
timings of surveillance and study type. Analysis beyond
these descriptive steps will take an iterative approach
dependent upon the studies identified and data available
from these. We anticipate that minimal statistical ana-
lysis will be possible given the likely heterogeneity of the
included data. Should they be possible, the following
analytical steps will be taken.
Narrative analyses
Narrative synthesis of the quantitative data will focus on
the features of each surveillance programme reported
and seek to identify key themes within the outcomes,
taking into account the assessments of risk of bias. The
narrative analysis will be split according to cancer type.
For each cancer type, data will be reported of number of
studies, patients and relapses included. Where reported,
we will summarise how relapses were diagnosed (by sur-
veillance or by symptoms). We will report any survival
data presented by the studies. If reported by the studies,
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we will then present any data on the number of images
performed (including radiation dose received) and any
cost-effectiveness, qualitative or psychological distress
indicator data.
Meta-analysis
Where appropriate, data will be synthesised using a ran-
dom effects meta-analysis using the R programming en-
vironment [9]. The meta-analysis will be based on ratio
measures or survival duration, if provided, and only if
sufficient clinical homogeneity exists. Inverse variance
random effects meta-analysis will be used given the an-
ticipated clinical heterogeneity in terms of population
and intervention.
Heterogeneity will be explored both clinically and sta-
tistically. Clinical evaluation of heterogeneity will con-
sider the differences in the surveillance programmes
assessed, different tumour types and ages of patient in-
cluded in the study and other factors such as healthcare
service design. Statistical heterogeneity will be examined
using χ2 tests, the I2 and tau2 statistics and by visual in-
spection of the forest plots.
Subgroup analyses
Subgroup analyses and sensitivity analyses will be per-
formed, including but not limited to tumour type, pres-
ence residual tumour, imaging techniques, timing and
duration of the surveillance imaging and type of health
care service.
Tumour type Studies will be analysed separately by
tumour type, given that the benefits of a screening
programme such as routine surveillance imaging depend
upon there being an effective intervention for relapse,
with intervention at a pre-symptomatic phase leading to
better outcomes [10]. The likelihood of such an inter-
vention varies between tumour types and thus has a
significant impact of the usefulness of surveillance
imaging.
No evidence of disease vs stable residuals Where pos-
sible, studies, or subgroups within studies, will be ana-
lysed according to the status of patients’ disease at the
start of routine surveillance imaging. Patients with stable
residual disease might be considered at increased risk of
relapse compared to those with no evidence of disease
and as such might be more likely to benefit from routine
surveillance imaging to identify this.
Imaging technique Studies using different imaging
techniques will be analysed separately given that the dif-
ferent modalities may have different diagnostic test ac-
curacies for identifying relapse and thus may identify
relapse at different stages. Thus, imaging with one
modality may be more or less effective as a routine sur-
veillance programme than another, even within the same
tumour type.
Timing of surveillance (i.e. length of intervals) The
frequency of surveillance imaging is likely to impact on
the risk of length time bias and thus impact on the sur-
vival benefits of the surveillance programme. It may also
inversely impact on psychological outcomes, with fre-
quent scans increasing the acuity of the sawtooth mood
variation of “scanxiety”. The frequency will be grouped
by number of months between scans, recognising that
most programmes will use 3-, 4-, or 6-monthly imaging
particularly in the early phases after treatment.
Duration of surveillance (i.e. time from start to end
of surveillance programme) The duration of surveil-
lance imaging may impact upon the psychological im-
pacts, cost-effectiveness and other potential disadvantages
of screening programmes. This subgroup will be evaluated
by grouping the duration of imaging into 6-monthly
blocks from the start of the programme.
Type of healthcare service The type of healthcare ser-
vice (public or private) may impact upon the costs of
imaging, as well as attitudes towards surveillance im-
aging for professionals and families. The subgroup will
evaluate any cost data according to public or private
healthcare.
Sensitivity analyses
Potential areas of heterogeneity will be explored using
sensitivity analyses, including study design (including
restricting analyses to randomised controlled trials only),
studies reported as conference abstracts only, risk of bias
assessed by components, definitions of overall survival
(age at death vs OS from original diagnosis vs other) and
the location of the study, which provides information on
the surrounding healthcare system.
We will also explore whether the original treatment
programme for the malignancy has an impact on relapse
detection, as well as overall survival. In the situation of
different original treatment programmes, the ability of
the relapse to be salvaged is likely to change and directly
affect survival. Additionally, different original treatment
programmes may affect the speed of development, or lo-
cation, or tracer-uptake characteristics of relapse; this
may lead to a difference in the ability of the imaging
programme to detect relapse occurring.
Publication bias
The risk of publication bias will be explored if there are
≥ 5 comparative studies reporting the same outcome
using contour-enhanced funnel plots and Harbord and
Morgan et al. Systematic Reviews           (2019) 8:168 Page 6 of 9
Peters tests [7]. We anticipate that the risk of publica-
tion bias in this field will be relatively large, as studies
are likely to be small and performed as secondary ana-
lyses within larger studies (thus showing a lag time bias).
Qualitative analysis
Any qualitative data will be analysed using thematic ana-
lysis to combine data relating to perceived risks and ben-
efits of routine surveillance imaging, and experiences
related to the routine surveillance imaging process, sepa-
rated according to stakeholder group (patient, family,
professional, etc.). The analysis will explore the impact
of different methods of data collection, the patient’s out-
come (those who experienced relapse compared with
those who did not), tumour type and the different fea-
tures of the routine surveillance imaging programme
(imaging type, timing, duration and healthcare service
setting). Coding will be independently performed by two
researchers and then discussed within the research team.
Methods of dissemination
The dissemination plan for this review has been devel-
oped alongside our PPI group. The dissemination plan
will need to vary dependent upon the findings of the re-
search, with emphasis on different stakeholders being in-
formed dependent upon the certainty of the findings
and the likely impact of these. Dissemination will in-
clude traditional methods including journal manuscripts,
conference posters and presentations, with data reported
according to PRISMA guidelines [11]. Simultaneously,
we will seek to disseminate results to patients, families,
healthcare professionals, researchers and research fun-
ders through methods such as infographics of key find-
ings, promotional videos, social media updates and
presentations. The study team (researchers and PPI
group) feels that one of the most important aspects of
the dissemination plan is to provide a layered approach
to allow people to access as much or as little informa-
tion as they would like about the research.
Discussion
This review has one of three potential outcomes: (1) that
routine surveillance imaging conveys a survival benefit,
(2) that routine surveillance imaging does not convey a
survival benefit or (3) that there is insufficient evidence
to answer the research question. The impact of each of
these potential outcomes is discussed below.
If the review finds that routine surveillance imaging is
beneficial, it will provide information on the groups of
patients who may benefit, and may also be able to com-
ment on the optimal timing and duration of imaging,
dependent upon the evidence available.
If this systematic review finds that routine surveillance
imaging does not convey a survival benefit to children
and young people with extra-cranial solid tumours, this
could have significant benefits. As discussed above, redu-
cing exposure to radiation, anaesthesia, scan anxiety and
risks of false-positive results could dramatically improve
the current patient experience and future health of sur-
vivors of childhood cancer, whilst also conveying finan-
cial and service benefits. Should this be the case, the
work has the potential to impact clinical practice rapidly,
with the systematic review process being relatively fast
compared to primary research and implementation of
the work requiring minimal further costs after the estab-
lishment of the results.
If the review finds that there is insufficient evidence to
address the questions surrounding routine surveillance
imaging, it will have identified the current gaps in the
literature and be able to define the design of future stud-
ies that are most likely to provide the evidence needed.
Appendix 1
Study eligibility decision form
Person completing form:
Title of study:
Authors of study:
1. Does the study include ≥ 50% children or young
adults aged less than 25 years (or is data for this
group extractable)?
Yes/Unclear/No
2. Does the study include patients who have
completed treatment for a malignant extracranial
solid tumour and have no evidence of active and
ongoing disease at end of treatment?
Yes/Unclear/No
3. Does the study include patients treated in a high
income setting (or is the data for this group
extractable)?
Yes/Unclear/No
4. Does the study examine routine surveillance
imaging outcomes (with or without a control/
comparisor group)?
Yes/Unclear/No
5. Does the study assess any of the outcomes defined
in the review protocol?
Yes/Unclear/No
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6. Final decision (Include only if all 5 previous
questions answered Yes, Exclude if any No.):
Include/Exclude/Unsure
7. If exclude, main reason for exclusion:
Appendix 2
Data extraction tool
General information
Person performing data extraction:
Date of data extraction:
Study title:
Study Author, Year:
Language:
Country (or countries) in which research was
performed:
Source of funding:
Study Information
Stated aim of study:
Study design:
Appropriate risk of bias tool completed:
Inclusion criteria:
Exclusion criteria:
Definition of no evidence of active or ongoing disease:
Routine imaging used (please complete information
for each imaging modality separately):
Imaging modality: X-ray/ultrasound/CT/MRI/bone
scan/other
Site of imaging (e.g. affected site, abdomen, chest):
Frequency of imaging (e.g. every 6 months):
Duration of imaging programme (e.g. over 5 years):
Details of reporting/quality control:
Comparator/control group (if present):
Details of randomisation/selection of cohorts:
Participants
Number of participants:
Number in each group:
Number withdrawn:
Number included in analysis:
Age – provide details for each group:
Sex – provide details for each group:
Ethnicity (if given):
Socio-economic status (if given):
Disease(s):
Other important population factors (e.g. any patients
with hereditary predisposition syndromes):
Are recruitment/refusal to consent numbers given? If
so, please record details including, if given, number, dis-
tribution, reasons for declining:
Outcomes
Definition of relapse used:
Primary outcome(s), including definition of each:
Secondary outcome(s), including definition of each:
Appendix 3
Assessment of risk of bias – stratified approach to
ROBINS-I
First stage assessment
1) Is there potential for confounding of the effect of
intervention in this study?
2) Was selection of participants into the study (or ana-
lysis) based on participant characteristics observed after
the start of intervention?
3a) Were there deviations from the intended surveil-
lance programme or control arm beyond expected in
usual practice?
3b) Were these unbalanced and likely to have affected
outcome?
4a) Were outcome data available for all, or nearly all,
participants?
4b) Is there evidence that results were robust to the
presence of missing data?
5a) Could the outcome measure have been influenced
by knowledge of the intervention received?
5b) Were outcome assessors aware of the intervention
received by study participants?
5c) Were any systematic errors in measurement of the
outcome related to intervention received? (e.g. survival
measured from diagnosis of relapse)
6) Is the reported effect estimate likely to be selected
on the basis of the results from multiple outcome mea-
surements within the outcome domain, multiple analyses
of the intervention-outcome relationship or different
subgroups?
Second stage assessment
Full ROBINS-I tool as published [8].
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Additional file 1: PRISMA-P guidelines. (DOCX 33 kb)
Additional file 2: Search strategy. (DOCX 14 kb)
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